AdvanTIG-203: results and biomarkers in esophageal cancer

Nature Communications · Published 2026-09-18

A randomized phase II trial evaluates dual checkpoint blockade and exploratory immune biomarkers in advanced esophageal squamous cell carcinoma.

The 125-patient trial did not meet its primary objective-response endpoint. Adding ociperlimab to tislelizumab did not significantly improve efficacy. Exploratory analyses identified immune-inflamed signatures that warrant further investigation.

Qi Zhao’s role: Co-author, Sun Yat-sen University Cancer Center.

Read the paper · PubMed

Source: publication record. Checked on 19 November 2026.

Qi Zhao
Qi Zhao
Professor of Sun Yat-sen University Cancer Center

Cancer bioinformatics and multi-omics research on tumor heterogeneity, the immune microenvironment and treatment response.